MD Anderson is a big organization, but it’s welcoming and it makes you feel safe.
A team of some of the world's most renowned experts works together to give you personalized care, communicating closely with you and each other at every step. Your care team draws from a full range of the latest, most advanced treatments for myelodysplastic syndrome. Since long-term follow up care often is needed, we maintain a close relationship with your referring physician.
And at MD Anderson you're surrounded by the strength of one of the nation's largest and most experienced comprehensive cancer centers, which has all the support and wellness services needed to treat the whole person – not just the disease.
Over the past few years, the care of patients with MDS and the understanding of this disease have improved significantly. This has resulted in the development of new therapies, many of which were studied extensively at MD Anderson, including decitabine (Dacogen®) and azacitidine (Vidaza®), which now are considered standard of care. Our researchers also have been instrumental in finding out how the disease begins on a molecular basis and how to determine potential outlooks.
At MD Anderson's Leukemia Center, you benefit from one of the most active research programs in the United States. This means we are able to offer a range of clinical trials (research studies) of new treatments for myelodysplastic syndrome.
Understanding a disease is the first step toward finding the right care. Get the facts about myelodysplastic syndrome, including the different types, how it starts and who’s at risk.
Planning a visit to MD Anderson? Download our free mobile app through Apple's app store or Google Play.
BY MD Anderson
April 21, 2014